As Lurbinectedin is being tested as a second line treatment for patients with relapsed small cell lung cancer after platinum based chemotherapy, can the use of drug releasing nanoparticles be a more focused delivery option for this drug?
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30068-1/fulltext
https://immuno-oncologynews.com/2020/02/24/fda-grants-priority-review-to-lurbinectedin-for-small-cell-lung-cancer/